Hyaluronic Acid
| Evidence Level: L3 | Predicted Indications: 9 |
Table of Contents
Hyaluronic Acid: Sjogren syndrome
One-Sentence Summary
Hyaluronic acid is marketed in Australia as sodium hyaluronate 1 mg/mL eye drops. The TxGNN model predicts it may help with Sjogren syndrome, mainly as symptomatic relief of ocular surface dryness rather than treatment of the underlying autoimmune disease. Support comes from 1 loosely related Phase 3 trial and a small body of published studies, including a comparative study in Sjögren patients. No Phase 3 trial of hyaluronic acid itself in Sjogren syndrome appears in the data compiled for this report.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not recorded in the local data |
| Predicted New Indication | Sjogren syndrome |
| TxGNN Prediction Score | 0.9974 |
| Evidence Level | L3 |
| Australia Market Status | Listed on the PBS Schedule (1 of 1 items) – TGA (ARTG) registration status is not included in this data |
| Number of PBS Items | 1 (valid: 1) |
| Recommended Decision | Proceed with Guardrails |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available. Based on known information, hyaluronic acid is a water-retaining glycosaminoglycan used as a topical lubricant. It is expected to hydrate and stabilise the tear film.
Sjogren syndrome is an autoimmune condition that reduces tear and saliva production, so the ocular surface and mouth become dry. Hyaluronic acid eye drops could plausibly ease these symptoms through lubrication and tear-film stabilisation. The same property underlies its use as a vehicle in other formulations, such as hyaluronate sheets for dry mouth.
This is symptomatic relief only. Nothing in the data compiled suggests hyaluronic acid modifies the autoimmune process itself. Comparative studies in Sjögren patients exist, but they are small and mostly compare formulations or use hyaluronic acid as a carrier for another active drug.
Clinical Trial Evidence
No clinical trials registered specifically for hyaluronic acid in Sjogren syndrome are listed in the data compiled for this report. The one linked Phase 3 trial (NCT02257957, completed, 30 participants, platelet-rich plasma injection for severe ocular surface disease) was graded as indirect. Hyaluronic acid appears there only as a likely comparator or background treatment, so it does not directly support this prediction.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 28557655 | 2017 | Comparative clinical study | J Ocul Pharmacol Ther | Compared tear-film stability after hyaluronic acid versus cross-linked hyaluronic acid eye drops in patients with Sjögren syndrome-related ocular dryness |
| 28375792 | 2017 | Clinical trial (HA as vehicle) | J Ocul Pharmacol Ther | Evaluated 0.3% cortisol phosphate in a hyaluronic acid vehicle in Sjogren syndrome; hyaluronic acid’s own effect was not isolated |
| 30830076 | 2019 | Clinical study | Vestn Oftalmol | Assessed the antioxidant effect of artificial tears in severe keratoconjunctivitis sicca in Sjögren patients |
| 23890196 | 2014 | Comparative clinical/experimental study | Acta Ophthalmol | Assessed sodium hyaluronate as a diluent for autologous serum eye drops |
| 15110955 | 2004 | Review | Rev Med Interne | Overview of treatments used for ocular dryness (xerophthalmia) in Sjögren syndrome |
| 35370264 | 2022 | Formulation study | Biol Pharm Bull | Hyaluronate sheets containing pilocarpine as a topical treatment for dry mouth, including in Sjögren syndrome |
| 9797560 | 1998 | Observational (biomarker) | Ann Rheum Dis | Measured salivary and serum hyaluronic acid concentrations in primary Sjögren syndrome |
| 40346044 | 2025 | Preclinical | Int J Oral Sci | Hydrogel platform for expanding human salivary acinar cell spheroids, relevant to dry mouth in Sjögren syndrome |
Australia Market Information
| ARTG Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| ARTG 14354L | Hylo-Fresh | Eye drops containing sodium hyaluronate 1 mg per mL, 10 mL | Not available |
This is the only licence recorded, and it is valid. It is a single-ingredient ophthalmic product.
Safety Considerations
- Drug Interactions (both Moderate): two interactions were identified, both with topical preservatives.
- Cetylpyridinium (topical)
- Benzalkonium (topical)
No key warnings or contraindications are available in the data compiled. Please refer to the TGA-approved Product Information (PI) for full safety information.
Conclusion and Next Steps
Decision: Proceed with Guardrails
Rationale: Hyaluronic acid eye drops are already marketed in Australia, and a comparative study in Sjögren patients supports a symptomatic role. However, there is no Phase 3 trial of hyaluronic acid itself in Sjogren syndrome, and any benefit would be limited to symptom relief.
To proceed, the following is needed:
- A controlled trial of hyaluronic acid eye drops in Sjögren patients, with a clear symptomatic endpoint
- Mechanism of action data
- Review of the PI for warnings and contraindications
- Guidance on preservative-related interactions, including with benzalkonium and cetylpyridinium
- Assessment of whether other routes (for example, oral or nasal) are suitable for dry mouth
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.